Leerink Swann set a $16.00 price target on Corium International Inc. (NASDAQ:CORI) in a research note released on Tuesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other research firms have also weighed in on CORI. FBR & Co set a $18.00 target price on Corium International and gave the company a buy rating in a report on Friday, August 5th. Zacks Investment Research lowered Corium International from a hold rating to a sell rating in a report on Tuesday, October 11th. Finally, Needham & Company LLC reissued a buy rating and issued a $15.00 target price on shares of Corium International in a report on Monday, September 26th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $12.25.
Shares of Corium International (NASDAQ:CORI) opened at 4.70 on Tuesday. Corium International has a 52 week low of $3.14 and a 52 week high of $9.93. The firm’s 50-day moving average is $5.04 and its 200-day moving average is $4.71. The stock’s market capitalization is $104.37 million.
Hedge funds have recently bought and sold shares of the stock. Opaleye Management Inc. raised its stake in Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock worth $1,390,000 after buying an additional 5,000 shares during the last quarter. RTW Investments LLC raised its stake in Corium International by 3.0% in the second quarter. RTW Investments LLC now owns 852,961 shares of the biopharmaceutical company’s stock worth $2,960,000 after buying an additional 24,629 shares during the last quarter. Finally, Paloma Partners Management Co bought a new stake in Corium International during the second quarter worth approximately $152,000. 88.35% of the stock is currently owned by institutional investors and hedge funds.
About Corium International